Daily Stock Analysis, CRL, Charles River Laboratories International Inc, priceseries

Charles River Laboratories International Inc. Daily Stock Analysis
Stock Information
Open
88.49
Close
87.81
High
88.63
Low
87.35
Previous Close
87.93
Daily Price Gain
-0.12
YTD High
89.59
YTD High Date
Feb 14, 2017
YTD Low
75.25
YTD Low Date
Jan 3, 2017
YTD Price Change
11.28
YTD Gain
14.74%
52 Week High
89.59
52 Week High Date
Feb 14, 2017
52 Week Low
67.20
52 Week Low Date
Nov 3, 2016
52 Week Price Change
14.92
52 Week Gain
20.47%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 6. 2015
64.65
Feb 2. 2015
68.45
18 Trading Days
5.88%
Link
LONG
Mar 4. 2015
76.61
Mar 24. 2015
81.93
14 Trading Days
6.94%
Link
LONG
Mar 31. 2016
75.94
Apr 19. 2016
80.10
13 Trading Days
5.48%
Link
Company Information
Stock Symbol
CRL
Exchange
NYSE
Company URL
http://www.criver.com
Company Phone
781-222-6000
CEO
James C. Foster
Headquarters
Massachusetts
Business Address
251 BALLARDVALE ST, WILMINGTON, MA 01887
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Laboratories & Research
CIK
0001100682
About

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide.

Description

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening preclinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs and chickens used in the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.